Results 31 to 40 of about 4,616 (237)

Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ)

Medicina, 2021
Medication-related osteonecrosis of the jaw (MRONJ) has become a well-known side effect of antiresorptive, and antiangiogenic drugs commonly used in cancer management.
Sven Otto, Suad Aljohani, Riham Fliefel, Sara Ecke, Oliver Ristow, Egon Burian, Matthias Troeltzsch, Christoph Pautke, Michael Ehrenfeld   +8 more
doaj   +1 more source

Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw

European Journal of Medical Research, 2023
Background Bisphosphonates (BPs) are widely used in clinical practice to prevent and treat bone metabolism-related diseases. Medication-related osteonecrosis of the jaw (MRONJ) is one of the major sequelae of BPs use. Early prediction and intervention of
Hong Mu, Ying Pang, Lili Liu, Jingbo Liu, Chunsheng Liu   +4 more
doaj   +1 more source

MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series

BMC Oral Health, 2023
Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases.
Rodolfo Mauceri, Martina Coppini, Massimo Attanasio, Alberto Bedogni, Giordana Bettini, Vittorio Fusco, Amerigo Giudice, Filippo Graziani, Antonia Marcianò, Marco Nisi, Gaetano Isola, Rosalia Maria Leonardi, Giacomo Oteri, Corrado Toro, Giuseppina Campisi   +14 more
doaj   +1 more source

Osteoporosis Management after the Occurrence of Medication-Related Osteonecrosis of the Jaw: A 13-Year Experience at a Tertiary Center [PDF]

Endocrinology and Metabolism
Background We investigated osteoporosis management strategies and clinical outcomes following the occurrence of medicationrelated osteonecrosis of the jaw (MRONJ).
Chun Ho Wong, Kimberly Hang Tsoi, Jingya Jane Pu, Nancy Su Jiang, Stacey Sheung Yi Chan, Connie Hong Nin Loong, Xincheng Zou, Carol Ho Yi Fong, Eunice Ka Hong Leung, Alan Chun Hong Lee, Chi Ho Lee, Kathryn Choon Beng Tan, Yu Cho Woo, Yu-xiong Su, David Tak Wai Lui   +14 more
doaj   +1 more source

Goodbye BRONJ… Hello MRONJ [PDF]

CRANIO®, 2016
Since the first reports in 2003 and 2004, osteonecrosis of the jaws (ONJ), associated with the bisphosphonate drugs used in the treatment of certain malignancies, and osteoporosis have been a promi...
openaire   +2 more sources

Medication-Related Osteonecrosis of the Jaw Spontaneously Occurred in a Patient with Chronic Myelogenous Leukemia Only by Imatinib: A Report of a Rare Case

Case Reports in Dentistry, 2021
The prevalence of medication-related osteonecrosis of the jaw (MRONJ) associated with molecular-targeted therapies such as bevacizumab and sunitinib has been constantly increasing in recent years.
Makiko Okubo-Sato, Kenji Yamagata, Satoshi Fukuzawa, Kazuhiro Terada, Fumihiko Uchida, Naomi Ishibashi-Kanno, Hiroki Bukawa   +6 more
doaj   +1 more source

Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches

Antioxidants, 2021
Medication-related osteonecrosis of the jaw (MRONJ) is one of the most interesting diseases in the field of maxillofacial surgery. In addition to bisphosphonates, the use of antiresorptive and antiangiogenic agents is known to be the leading cause ...
Sung-Woon On, Seoung-Won Cho, Soo-Hwan Byun, Byoung-Eun Yang   +3 more
doaj   +1 more source

Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw.

PLoS ONE, 2019
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event of bone-modifying agents used to prevent bone complications in cancer patients with bone metastasis.
Wakako Yatsuoka, Takao Ueno, Kanako Miyano, Yasuhito Uezono, Ayame Enomoto, Miku Kaneko, Sana Ota, Tomoyoshi Soga, Masahiro Sugimoto, Toshikazu Ushijima   +9 more
doaj   +1 more source

Adjuvant therapies for MRONJ: A systematic review

Bone, 2020
Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction caused by the use of antiresorptive antiangiogenic medication. Treating MRONJ is difficult and besides standard treatments, which are conservative medical and surgical approaches, there are some adjuvant therapies that might further stimulate healing.
Govaerts, Dries, Piccart, Frederik, Ockerman, Anna, Coropciuc, Ruxandra, Politis, Constantinus, Jacobs, Reinhilde   +5 more
openaire   +2 more sources

A retrospective study on odontogenic and non-odontogenic medication-related osteonecrosis of the jaw: Potential differences in clinical features and treatment outcomes

Journal of Dental Sciences
Background/purpose: Local infections, such as periodontal disease or apical lesions, and invasive dental procedures, such as tooth extraction, are thought to trigger medication-related osteonecrosis of the jaw (MRONJ) development.
Mizuho Ohnuma, Mitsunobu Otsuru, Keisuke Omori, Kota Morishita, Saki Hayashida, Sakiko Soutome, Kei-ichiro Miura, Masahiro Umeda, Tomohiro Yamada   +8 more
doaj   +1 more source